FDA Acceptance of NDA for Capivasertib by AstraZeneca
The FDA has accepted the NDA for Capivasertib, indicating progress in its regulatory review.
Therapeutic Area
Therapeutic area intelligence for AKT Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.